Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 0.14 and traded as high as GBX 0.15. Oxford BioDynamics shares last traded at GBX 0.12, with a volume of 69,249,742 shares traded.
Oxford BioDynamics Stock Performance
The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The stock has a market capitalization of £4.89 million, a PE ratio of -0.57 and a beta of 0.42. The firm’s fifty day moving average price is GBX 0.13 and its two-hundred day moving average price is GBX 0.20.
Oxford BioDynamics (LON:OBD – Get Free Report) last posted its earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
See Also
- Five stocks we like better than Oxford BioDynamics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
